(Q38092465)

28 August 2017

title

Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies (English)

1 reference

28 August 2017

0 references

Vaccinia virus

1 reference

Gerd Sutter

2

0 references

Asisa Volz

series ordinal

1

object named as

Asisa Volz

1 reference

28 August 2017

language of work or name

English

0 references

publication date

21 March 2013

1 reference

28 August 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

28 August 2017

volume

31

1 reference

28 August 2017

issue

39

1 reference

28 August 2017

page(s)

4235-4240

1 reference

MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Nonreplicating vaccinia vector efficiently expresses recombinant genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Cytotoxic T-lymphocyte activation involves a cascade of signalling and adhesion events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Stable antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Modified vaccinia virus ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Easy and efficient protocols for working with recombinant vaccinia virus MVA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Vaccination strategies to protect children against seasonal and pandemic influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

A Pandemic Influenza H1N1 Live Vaccine Based on Modified Vaccinia Ankara Is Highly Immunogenic and Protects Mice in Active and Passive Immunizations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

The immunological life cycle of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Experimental human challenge infections can accelerate clinical malaria vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Prime-boost vectored malaria vaccines: progress and prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

The use of nonhuman primate models of HIV infection for the evaluation of antiviral strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression f

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Effect of therapeutic immunization using Ad5/35 and MVA vectors on SIV infection of rhesus monkeys undergoing antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Partial protection against SIV challenge by vaccination of adenovirus and MVA vectors in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Smallpox vaccines: targets of protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Ectromelia virus: the causative agent of mousepox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Evaluation of smallpox vaccines using variola neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.016

10.1016/J.VACCINE.2013.03.016

7 January 2021

Identifiers

DOI

1 reference

28 August 2017

1 reference